Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Senzime AB ( (SE:SEZI) ) has issued an announcement.
Senzime AB welcomes the pre-announcement of new European pediatric guidelines for quantitative neuromuscular monitoring during anesthesia, revealed at the Euroanaesthesia 2025 congress. This development is significant for pediatric anesthesia, as it recommends EMG-based monitoring technology, aligning with Senzime’s TetraGraph system, which is FDA-cleared for use on patients as young as one month. The guidelines represent a substantial market opportunity for Senzime, addressing the historical lack of specialized pediatric solutions and aiming to reduce the risks of residual neuromuscular block in pediatric surgeries.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems to enhance perioperative patient safety. Their flagship product, the TetraGraph system, is renowned for its accurate monitoring of neuromuscular transmission during surgery. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
YTD Price Performance: -14.45%
Average Trading Volume: 188,021
Current Market Cap: SEK626.6M
Learn more about SEZI stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue